OBJECTIVE: A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule. METHODS: Patients received weekly intravenous infusions of oxaliplatin 40 mg/m, 5-FU 500 mg/m, and leucovorin 250 mg/m (3 weeks on, 1 week off). RESULTS: Twenty-three patients affected with metastatic (16) or locally advanced (7) pancreas adenocarcinoma were involved in this study. A total of 148 weeks of chemotherapy was delivered (median 2 courses each patient). Among 17 assessable patients, no objective response was registered and 4 patients had stable disease, whereas 13 had tumor progression. Median duration of stable disease was 14 weeks. Median time to progression of disease (TTP) was 11.6 weeks [95% confidence interval (CI), 7.6-5.6]. Kaplan-Meier estimated median overall survival (OS) was 17.1 week (95% CI, 4.0-30.1) and 3 months survival rate was 69.6%. Seven patients experienced grade 3 to 4 toxicity. The regimen was associated with 36% clinical benefit. CONCLUSIONS: The median TTP and median OS in this population with poor prognosis suggests some activity, however, only further investigations will be able to establish the clinical value of this combination.

Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer

SATOLLI, MARIA ANTONIETTA;BELLONE, Graziella;
2009-01-01

Abstract

OBJECTIVE: A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule. METHODS: Patients received weekly intravenous infusions of oxaliplatin 40 mg/m, 5-FU 500 mg/m, and leucovorin 250 mg/m (3 weeks on, 1 week off). RESULTS: Twenty-three patients affected with metastatic (16) or locally advanced (7) pancreas adenocarcinoma were involved in this study. A total of 148 weeks of chemotherapy was delivered (median 2 courses each patient). Among 17 assessable patients, no objective response was registered and 4 patients had stable disease, whereas 13 had tumor progression. Median duration of stable disease was 14 weeks. Median time to progression of disease (TTP) was 11.6 weeks [95% confidence interval (CI), 7.6-5.6]. Kaplan-Meier estimated median overall survival (OS) was 17.1 week (95% CI, 4.0-30.1) and 3 months survival rate was 69.6%. Seven patients experienced grade 3 to 4 toxicity. The regimen was associated with 36% clinical benefit. CONCLUSIONS: The median TTP and median OS in this population with poor prognosis suggests some activity, however, only further investigations will be able to establish the clinical value of this combination.
2009
32
44
48
http://ovidsp.tx.ovid.com/sp-2.3.1b/ovidweb.cgi?QS2=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
pancreatic cancer; oxaliplatin; 5-fluorouracil
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L.
File in questo prodotto:
File Dimensione Formato  
Satolli_456033.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 108.54 kB
Formato Adobe PDF
108.54 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/138057
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 34
social impact